EP04.01-003 Is It Time for a New Paradigm in Care of Young Cancer Patients? A Retrospective Study

advances in treatment of lung cancer (LC) over the past two decades, with target agents (tyrosine-kinase inhibitors, TKI) and immunotherapy (IO) have contributed to improve survival in patients with metastatic non-small cell lung cancer (NSCLC). About 40% of LC patients seek the emergency department at least once during the course of the disease and 63% of these visits lead to hospital admission. Of all intensive care unit (ICU) admissions among patients with solid cancers, 27% refer to LC patients.